Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5VYS8
UPID:
TUT7_HUMAN
Alternative names:
Zinc finger CCHC domain-containing protein 6
Alternative UPACC:
Q5VYS8; Q5H9T0; Q5VYS5; Q5VYS7; Q658Z9; Q659A2; Q6MZJ3; Q8N5F0; Q96N57; Q96NE8; Q9C0F2; Q9H8M6
Background:
Terminal uridylyltransferase 7 (TUT7), also known as Zinc finger CCHC domain-containing protein 6, plays a crucial role in mRNA decay by mediating the terminal uridylation of mRNAs with short poly(A) tails. It is essential for oocyte maturation and fertility, sculpting the maternal transcriptome by eliminating transcripts during oocyte growth. TUT7 is also involved in microRNA-induced gene silencing and acts as a suppressor of miRNA biogenesis through various uridylation mechanisms.
Therapeutic significance:
Understanding the role of Terminal uridylyltransferase 7 could open doors to potential therapeutic strategies.